Novo Nordisk A/S vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.8. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals.
| NVO | QDTE | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $71.70 | $36.60 |
52-Week Low | $35.29 | $26.85 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →